



# Thierry LOMBERGET

## Full Professor of Medicinal Chemistry Head of COSSBA team

UMR CNRS 5246 – ICBMS – COSSBA team  
Université Claude Bernard LYON 1  
ISPB - Faculté de Pharmacie de LYON  
8, avenue Rockefeller  
69373 LYON cedex 08 – FRANCE

 [thierry.lomberget@univ-lyon1.fr](mailto:thierry.lomberget@univ-lyon1.fr)  
 +33 (0)4 78 77 70 82



**ORCID:** 0000-0002-4071-0002  
Born on the 3<sup>rd</sup> of July 1973

### Education

---

**2010: Research Habilitation (HDR)** Université Claude Bernard Lyon 1 (UCBL)  
« From palladium chemistry to the design of new CK2 inhibitors. »

**2002: PhD in Organic Chemistry** UCBL « New palladium-catalyzed strategies to 1,3-bis-exocyclic dienes and 1,3,5-trienes. Study of their reactivities. Approach of the synthesis of (±)-Dichroanal B. »  
Research supervisors: Dr. G. BALME and Dr. D. BOUYSSI

**1999: Master 2 in Advanced Organic Chemistry** UCBL

**1994: University Diploma of Technology (DUT) in Chemistry** (superior technician diploma) UCBL

### Professional and academic experiences

---

**September 2016 to present: Full Professor of Medicinal Chemistry**  
EA 4446 (sept 2016 – december 2020), then UMR CNRS 5246 – ICBMS – LYON Faculty of Pharmacy – ISPB

**December 2010 – august 2016: Associate professor of medicinal chemistry**

**September 2005 – december 2010: Assistant professor of medicinal chemistry**

Research units: EA 3741 (2005 – 2006), INSERM U863 (2007 – 2009), EA 4446 (2010 – august 2016)

**September 2004 – august 2005: Temporary Research and teaching assistant (ATER)**

Laboratoire de Chimie Thérapeutique, ISPB-Faculté de Pharmacie de Lyon, Pr. Roland BARRET

**November 2002 – august 2005: post-doctoral research assistant** University of Geneva, Pr. E. Peter KÜNDIG  
« Preparation of enantio-enriched naphthalene chromium tricarbonyl complexes. »

### Scientific production and expertise

---

- **35 publications** (1 *Adv. Synth. Cat.*, 2 *Angew. Chem. Int. Ed.*, 2 *Bioorg. Med. Chem. Lett.*, 3 *Chem. Commun.*, 1 *Chem. Sci.*, 1 *Chimia*, 1 *Eur. J. Med. Chem.*, 1 *J. Enzyme Inhib. Med. Chem.*, 4 *J. Med. Chem.*, 1 *Helv. Chim. Acta*, 1 *Org. Biomol. Chem.*, 2 *Org. Lett.*, 1 *Pharmaceuticals*, 1 *Rapid Commun. Mass Spectrom.*, 1 *Sci. Total Environ.*, 1 *Sci. Rep.*, 2 *Steroids*, 2 *Synlett*, 3 *Synthesis*, 2 *Tetrahedron*, 2 *Tetrahedron Lett.*), **h-index = 15 / 638 citations** (February 2023), **2 patents**, 7 oral communications, 21 posters, **4 invited lectures**.

- Reviewer for medicinal and organic chemistry journals and for funding applications.

- 6 supervisions and 5 co-supervisions of PhD students, 15 supervisions of Master 2 students.

### Research interests

---

**Drug design and chemical synthesis of molecules with potential therapeutic interests:** anticancer agents (targeting tubuline assembly into microtubules and kinases inhibitors) and inhibitors of P-glycoprotein-mediated MultiDrug Resistance. Design and synthesis of molecules interacting with viral and bacterial proteins. Pharmacochimistry, organic/heterocyclic/organometallic chemistry, steroids synthesis and functionalization.

Methodology in organic synthesis (nitrogen and oxygen heterocycles), analytic chemistry (LC/MS, chiral phases), synthesis of internal standards (labelled with stable isotopes) and metabolites.